An Overview on Novel Coronavirus (COVID-19)
In December 2019, a novel coronavirus (COVID-19) was reported in Wuhan, a city of 11 million people in central China. The initial cases were connected to exposures in a seafood market in Wuhan [1]. As of March 31, 2020, the WHO reported 697244 confirmed cases and 33257 confirmed deaths in 204 countries of the whole world. The infected people were experienced respiratory illness and coughs. Therefore, pathogen was soon identified as a COVID-19 which is closely related to sever acute respiratory syndrome CoV(SARS-CoV). Currently, there is no completely specific treatment against the COVID-19. Therefore, identifying effective antiviral medicines to combat the disease is an imperatively needed. An efficient approach to effective drug discovery is to test whether the existing antiviral drugs are effective in treating related COVID-19 viral infections. Also, clinical researches are rapidly growing on to find out the solution of COVID-19.
Opinion
In December 2019, a novel coronavirus (COVID-19) was reported in Wuhan, a city of 11 million people in central China. The initial cases were connected to exposures in a seafood market in Wuhan [1]. As of March 31, 2020, the WHO reported 697244 confirmed cases and 33257 confirmed deaths in 204 countries of the whole world. The infected people were experienced respiratory illness and coughs. Therefore, pathogen was soon identified as a COVID-19 which is closely related to sever acute respiratory syndrome CoV(SARS-CoV). Currently, there is no completely specific treatment against the COVID-19. Therefore, identifying effective antiviral medicines to combat the disease is an imperatively needed. An efficient approach to effective drug discovery is to test whether the existing antiviral drugs are effective in treating related COVID-19 viral infections. Also, clinical researches are rapidly growing on to find out the solution of COVID-19.
Till date, there are several drugs tested against COVID-19, such as favipiravir (T-705), remdesivir (GS- 5734), interferon, ribavirin, lopinavir-ritonavir, corticosteroids, nafamostat, penciclovir, chloroquine phosphate, azithromycin, hydroxychloroquine, nitazoxanide and chloroquine [2, 3, 4, 5, 6]. Nevertheless, unfortunately the aforementioned medicines are not able to perfectly cure COVID-19.
So, our suggestion is that protect yourself and others from infected person of COVID-19 by washing your hands or using a sanitizers/alcohol based rub frequently and not touching your face. If possible stay at home and aware about updated news on COVID-19. Therewithal, follow the guidelines of WHO, central and state governments. This is one of best and unique platform to fight against COVID-19 and save many lives.
Opinion
References
-
Zunyou W, Jennifer MM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama 323(13): 1239-1242.
-
Wang M, Ruiyuan C, Leike Z, Xinglou Y, Jia L, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research 3: 269-271.
-
Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, et al. (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT- PCR. Journal of Korean medical science 35(6): e79.
-
Gao J, Zhenxue T, Xu Y (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 14(1): 72-73.
-
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 4: 105932.
-
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 20: 105949.
- Solution-Processed Chiral Perovskites for Biomedical Applications
- Nanotechnology in Health Chemistry and Medicine: Current Challenges and Future Directions
- Human Exposure to Micro- and Nanoplastics: Pathways, Toxicity, and Intervention Strategies
- Exosome Nanomedicine for Cancer Therapy
- Micro and Nanoplastics–Plastisphere, Biotoxicity, Impact on Human Health, and Mitigation Strategies
- Process Validation of Cefixime Powder for Suspension Dosage Form, 50 mL